Short Interest in Kamada Ltd. (NASDAQ:KMDA) Declines By 68.6%

Kamada Ltd. (NASDAQ:KMDA) saw a significant decrease in short interest in the month of August. As of August 31st, there was short interest totalling 13,300 shares, a decrease of 68.6% from the August 15th total of 42,300 shares. Based on an average daily trading volume, of 27,900 shares, the days-to-cover ratio is presently 0.5 days. Currently, 0.1% of the shares of the stock are short sold.

Analyst Upgrades and Downgrades

Several analysts have issued reports on KMDA shares. StockNews.com raised shares of Kamada from a “hold” rating to a “buy” rating in a report on Wednesday, August 30th. TheStreet raised shares of Kamada from a “d+” rating to a “c-” rating in a report on Thursday, August 24th. Finally, HC Wainwright reissued a “buy” rating and set a $11.00 price objective on shares of Kamada in a research note on Thursday, August 17th.

Institutional Investors Weigh In On Kamada

Several large investors have recently made changes to their positions in KMDA. State of Tennessee Treasury Department purchased a new stake in Kamada during the 2nd quarter worth $38,000. Group One Trading L.P. increased its stake in Kamada by 103.7% during the 1st quarter. Group One Trading L.P. now owns 11,064 shares of the biotechnology company’s stock worth $61,000 after buying an additional 307,831 shares during the period. JPMorgan Chase & Co. purchased a new stake in Kamada during the 2nd quarter worth $83,000. Norges Bank purchased a new stake in Kamada during the 4th quarter worth $131,000. Finally, Citigroup Inc. increased its stake in Kamada by 2,620.0% during the 1st quarter. Citigroup Inc. now owns 36,938 shares of the biotechnology company’s stock worth $206,000 after buying an additional 35,580 shares during the period. Institutional investors and hedge funds own 34.08% of the company’s stock.

Kamada Stock Performance

NASDAQ:KMDA opened at $5.15 on Thursday. The company has a quick ratio of 0.75, a current ratio of 1.97 and a debt-to-equity ratio of 0.06. The company has a market cap of $230.82 million, a P/E ratio of 64.38 and a beta of 0.94. Kamada has a fifty-two week low of $3.72 and a fifty-two week high of $5.85. The firm’s 50 day moving average is $5.25 and its two-hundred day moving average is $4.95.

Kamada (NASDAQ:KMDA) last released its quarterly earnings data on Wednesday, August 16th. The biotechnology company reported $0.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.02 by $0.02. Kamada had a net margin of 2.35% and a return on equity of 7.42%. The company had revenue of $37.44 million during the quarter, compared to analyst estimates of $34.18 million. During the same quarter in the prior year, the business earned $0.07 earnings per share. Analysts expect that Kamada will post 0.06 EPS for the current year.

Kamada Company Profile

Kamada Ltd., together with its subsidiaries, provides plasma-derived protein therapeutics. It operates in two segments, Proprietary Products and Distribution. The company offers WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; VARIZIG for post exposure prophylaxis of varicella; and GLASSIA for intravenous AATD.